Compare McKesson Corporation (MCK) vs Nike Inc (NKE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Nike Inc — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Nike Inc trades at $34.71 (market cap $51.60B). The key difference: McKesson Corporation is far larger — about 2.1× Nike Inc's market cap, and Nike Inc pays the higher dividend (4.72%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Nike Inc for 155 Days on average.
| MCK | NKE | |
|---|---|---|
Market Cap | $108.46B | $51.60B |
Volume | 712,607 | 43,506,062 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $69.68 |
52-Week Low | $725.17 | $33.87 |
Typical Hold Time | 74 Days | 155 Days |
Enterprise Value | $115.00B | $54.30B |
Dividend Yield | 0.4% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Nike (NKE) trades at $34.74, up 1.11% with bearish technical signals despite recent earnings beats. The company faces revenue pressure with FY2025 sales declining to $46.31B and net margin compressing to 6.74%. Analyst consensus remains positive with a $36.98 price target, though technical indicators show 16 sell signals against 2 buy signals. Recent news highlights challenges in China and EMEA markets while emphasizing Nike's strong brand positioning.
Nike's investment case balances strong brand equity against near-term operational headwinds. The stock offers value at 16.62 P/E with 21.56% ROE, but investors face risks from sluggish consumer demand and margin pressure. The upcoming Q4 2026 earnings on June 30 will be critical for confirming turnaround progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
